Literature DB >> 29529700

Articulating Spacers as a Modified One-Stage Revision Total Knee Arthroplasty: A Preliminary Analysis.

Ahmed Siddiqi1, Nicole E George2, Peter B White3, Bartlomiej W Szczech2, John V Thompson4, Jennifer I Etcheson2, Chukwuweike U Gwam2, Alexander T Caughran2, Ronald E Delanois2, James Nace2.   

Abstract

INTRODUCTION: Periprosthetic joint infection (PJI) following primary total knee arthroplasty (TKA) is a challenging complication for surgeons and patients alike. Although two-stage revision arthroplasty remains the gold standard PJI management in the United States, one-stage revision has had success in many parts of Europe. The aim of this study was to retrospectively review: 1) ultimate treatment success; 2) necessary antibiotic duration; 3) change in knee range of motion (ROM); and 4) final Knee Society Scores (KSS) in a case series of patients managed with retention of articulating antibiotic spacers following PJI.
MATERIALS AND METHODS: A retrospective review was performed on all patients treated for chronic PJI after primary TKA with retention of articulating antibiotic spacers at a minimum of one-year follow-up. Descriptive analysis was utilized to evaluate demographic characteristics, discharge destination, follow-up and antibiotic durations, Knee Society Score (KSS), and rates of treatment failure. Paired-Samples t-Tests were utilized to evaluate mean changes in flexion and extension between the preoperative and postoperative time periods.
RESULTS: Our final cohort included 29 patients who were managed with articulating spacer retention at a mean follow-up of 16.8 (range, 12.0 to 23.1) months, with 21 patients (72.4%) medically unfit for multiple surgeons and eight patients (27.6%) satisfied with their function. Mean age was 61.3 (range, 41 to 85) years and mean Charlson Comorbidity Index (CCI) was 6.1 (mean, 0 to 12). The predominant infecting organism was Methicillin-Resistant Staphylococcus aureus (MRSA), which was involved in eight patients (27.6%). There was a significant increase in postoperative knee flexion (+14.7°; p<0.001) and no decrease in postoperative knee extension (+2.3°; p=0.361). Treatment success in our cohort was 79.3% (23 patients), with four patients (13.8%) having chronic wound drainage and two patients (6.9%) requiring multiple spacer exchanges. Sixteen patients (55.2%) were able to complete their antibiotic regimen, with the remaining patients unable to discontinue their antibiotics by latest clinic follow-up. DISCUSSION: One-stage exchange arthroplasty offers the advantage of a single procedure with analogous failure rates compared to two-stage exchange, decreases hospitalization, and improves cost-effectiveness, which is paramount in today's healthcare environment. To our knowledge, this is the first study in the United States to evaluate outcome scores, function, and success rate of a modified one-stage revision TKA technique. Although we are unable to make definitive conclusions based on the small sample size, the outcomes in this study are encouraging.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29529700

Source DB:  PubMed          Journal:  Surg Technol Int        ISSN: 1090-3941


  3 in total

1.  Treatment options in PJI - is two-stage still gold standard?

Authors:  Igor Lazic; Christian Scheele; Florian Pohlig; Rüdiger von Eisenhart-Rothe; Christian Suren
Journal:  J Orthop       Date:  2021-01-20

2.  Articulating vs Static Spacers for Native Knee Infection in the Setting of Degenerative Joint Disease.

Authors:  Jessica Hooper; Prerna Arora; Shanthi Kappagoda; James I Huddleston; Stuart B Goodman; Derek F Amanatullah
Journal:  Arthroplast Today       Date:  2021-03-11

3.  Application of 3D Printing-Assisted Articulating Spacer in Two-Stage Revision Surgery for Periprosthetic Infection after Total Knee Arthroplasty: A Retrospective Observational Study.

Authors:  Lingtong Kong; Jiawei Mei; Wufei Ge; Xiansheng Jin; Xiaoxuan Chen; Xianzuo Zhang; Chen Zhu
Journal:  Biomed Res Int       Date:  2021-02-08       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.